Drug intelligence / Profile preview

PKM-011

Development stage: Preclinical
Lead developer: PKMed
Modality: Small Molecules
Administration: Intraarticular

Overview

**PKM-011** is a preclinical **small-molecule** drug candidate being developed by **PKMed** for **osteoarthritis**. It is described by the company as a **long-acting colchicine derivative** formulated for **intra-articular injection**, and is characterized as an early-stage **disease-modifying osteoarthritis drug** project derived from PKM-01. No specific molecular target has been publicly disclosed, but the program appears intended to deliver prolonged local colchicine-like anti-inflammatory and potentially disease-modifying activity within the joint.

Beyond the preview

Go deeper on PKM-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PKM-011.

Explore the full profile